1. Compound Identification
| Property | Value |
|---|---|
| Common Name | N-Acetylcysteine (NAC) |
| IUPAC Name | (2R)-2-acetamido-3-sulfanylpropanoic acid |
| CAS Registry Number | 616-91-1 |
| Molecular Formula | C₅H₉NO₃S |
| Molecular Weight | 163.19 g/mol |
| Structure | Acetylated derivative of the amino acid L-cysteine; contains a free sulfhydryl (−SH) group |
| Solubility | Freely soluble in water and ethanol |
| pH (10% aqueous solution) | 2.0–2.8 |
| Regulatory Status (US) | Approved as a prescription drug (mucolytic agent, acetaminophen overdose antidote); previously marketed as a dietary supplement under DSHEA; FDA issued guidance in 2022 questioning its supplement status under the drug preclusion clause |
| Regulatory Status (EU) | Approved mucolytic; available OTC in many EU member states |
| WHO Essential Medicines List | Listed as antidote (acetaminophen poisoning) |
| Pharmacopeial Monographs | USP, Ph. Eur., BP |
2. Therapeutic Application
Indication: Biofilm disruption adjunct to standard antibiotic therapy in adult patients with chronic rhinosinusitis (CRS), including CRS with nasal polyps (CRSwNP) and CRS without nasal polyps (CRSsNP).
Target Population: Adults (≥18 years) diagnosed with CRS per EPOS 2020 criteria — defined as symptomatic inflammation of the sinonasal mucosa persisting ≥12 weeks — in whom bacterial biofilms are suspected or confirmed as a contributor to treatment failure or disease recurrence. This includes patients who are candidates for or have undergone endoscopic sinus surgery (ESS).
Clinical Rationale:
CRS affects 1–12% of the global adult population and generates substantial morbidity, healthcare utilization, and quality-of-life impairment (Rosenfeld et al., 2007; Beule, 2015). Bacterial biofilms have been identified on the sinonasal mucosa in 42–80% of CRS patients undergoing surgery (Foreman et al., 2009; Psaltis et al., 2008). These biofilms — three-dimensional communities of bacteria encased in a self-produced extracellular polymeric substance (EPS) matrix — confer up to 1,000-fold increased antibiotic resistance compared to planktonic (free-floating) bacteria (Stewart & Costerton, 2001). The biofilm-forming species most commonly implicated in CRS are Staphylococcus aureus (detected in up to 60% of CRS cultures; Jotic et al., 2025) and Pseudomonas aeruginosa.
Standard CRS management (systemic antibiotics, topical corticosteroids, saline irrigation, and ESS when refractory) often fails to eradicate biofilm-associated bacteria, leading to recurrent disease and repeat surgeries. NAC is a well-characterized, inexpensive, widely available compound with an established safety profile across multiple routes of administration (oral, inhaled, intravenous, topical irrigation). Its free sulfhydryl group provides a chemical mechanism for disrupting EPS matrix integrity, making it a rational adjunct to antibiotics for improving bacterial eradication in biofilm-associated CRS.
3. Proposed Protocol
The following protocols are derived from published clinical and in vitro studies. They are presented here as enabling descriptions for defensive prior art purposes.
Protocol A — Sinus Irrigation (Post-ESS or Active CRS)
| Parameter | Value | Source |
|---|---|---|
| Compound | N-Acetylcysteine (NAC), pharmaceutical grade | — |
| Dose per irrigation | 1,600 mg total (two ampules of 800 mg/4 mL) dissolved in 250 mL 0.9% normal saline | Wee et al., 2024 (RCT) |
| Effective concentration | 6.4 mg/mL | Calculated from protocol |
| Route | Sinus irrigation (125 mL per nostril) | Wee et al., 2024 |
| Frequency | Three times daily | Wee et al., 2024 |
| Duration | 30 days (minimum); may extend based on clinical response | Wee et al., 2024 |
| Concurrent therapy | Standard postoperative regimen: amoxicillin/clavulanate ×7 days + topical fluticasone furoate 220 μg/nostril daily | Wee et al., 2024 |
Protocol B — Oral Adjunct (Systemic Biofilm Disruption Support)
| Parameter | Value | Source |
|---|---|---|
| Compound | N-Acetylcysteine, oral capsules or effervescent tablets | — |
| Dose | 600 mg twice daily (1,200 mg/day) | Blasi et al., 2016 (review of respiratory biofilm protocols); Millea, 2009 |
| Route | Oral | — |
| Frequency | Twice daily | — |
| Duration | 4–12 weeks concurrent with antibiotic therapy | — |
| Rationale | Systemic glutathione precursor support; reduction of oxidative stress in sinonasal mucosa; potential systemic antibiofilm contribution | Blasi et al., 2016 |
Protocol C — Nebulized (Direct Airway Delivery)
| Parameter | Value | Source |
|---|---|---|
| Compound | N-Acetylcysteine, 10% or 20% solution (100–200 mg/mL) | Standard mucolytic formulations (USP) |
| Dose | 3–5 mL of 10% solution (300–500 mg) per nebulization session | Standard mucolytic dosing per USP/prescribing information |
| Route | Nebulized inhalation directed at sinonasal passages | — |
| Frequency | 2–4 times daily | — |
| Duration | 2–4 weeks | — |
| Note | May cause bronchospasm in asthmatic patients; pre-treatment with bronchodilator recommended | Standard NAC prescribing precaution |
4. Mechanism of Action
NAC disrupts bacterial biofilms in chronic rhinosinusitis through multiple convergent mechanisms:
4.1 — Disruption of the Extracellular Polymeric Substance (EPS) Matrix
The bacterial biofilm matrix is composed of polysaccharides, proteins, and extracellular DNA (eDNA) held together in part by disulfide bonds and other cross-links. NAC’s free sulfhydryl (thiol; −SH) group acts as a reducing agent that cleaves disulfide bonds (−S−S−) within matrix glycoproteins and structural proteins, destabilizing the three-dimensional scaffold of the biofilm (Dinicola et al., 2014; Olofsson et al., 2003). This results in:
- Physical loosening and detachment of the biofilm from the mucosal surface
- Release of previously adherent bacterial cells into a planktonic (free-floating) state susceptible to antibiotics and immune clearance
- Reduction in extracellular polysaccharide production by 27.6% at 0.5 mg/mL and 44.6% at 1 mg/mL in P. aeruginosa biofilms (Zhao & Liu, 2010)
4.2 — Enhanced Antibiotic Penetration
An intact biofilm matrix physically blocks antibiotic diffusion into deeper bacterial layers. By degrading and thinning the EPS matrix, NAC increases antibiotic penetration to metabolically active and persister cells in the biofilm interior. This has been demonstrated in vitro with combinations of NAC + ciprofloxacin (Zhao & Liu, 2010), NAC + fosfomycin (Marchese et al., 2003), and NAC + linezolid (Leite et al., 2013) against clinically relevant pathogens.
4.3 — Inhibition of Biofilm Formation
At sub-inhibitory concentrations, NAC prevents initial bacterial adhesion and biofilm formation. In Staphylococcal isolates from CRS patients, 3.1 mg/mL (1/2 MIC) completely prevented biofilm formation in 77.8% of isolates (Jotic et al., 2025). This was consistent across isolates from both CRSwNP and CRSsNP patients, indicating that NAC’s antibiofilm activity targets matrix components rather than phenotype-specific pathways.
4.4 — Eradication of Established Biofilms
At supra-inhibitory concentrations (2×–8× MIC), NAC eradicates mature, pre-formed biofilms. 49.6 mg/mL (8× MIC) led to complete eradication of formed biofilm in 81.5% of Staphylococcal clinical isolates from CRS patients (Jotic et al., 2025). For P. aeruginosa, biofilm detachment begins at 0.5 mg/mL with complete disruption at 10 mg/mL (Zhao & Liu, 2010).
4.5 — Mucolytic Action
NAC cleaves disulfide bonds in mucin glycoproteins, reducing mucus viscosity in the sinonasal cavity. This facilitates mechanical clearance of disrupted biofilm fragments, bacteria, and inflammatory debris through irrigation and mucociliary transport.
4.6 — Antioxidant and Anti-inflammatory Effects
As a precursor to glutathione, NAC replenishes intracellular antioxidant reserves, scavenges reactive oxygen species (ROS) and reactive nitrogen species (RNS), and inhibits NF-κB activation. This reduces collateral tissue damage from the inflammatory response to biofilm-associated infection and may support mucosal healing (Jotic et al., 2025).
5. Evidence Summary
| Study | Year | Design | Population / Model | NAC Protocol | Key Findings |
|---|---|---|---|---|---|
| Jotic A, Cirkovic I, Bozic D, et al. Microorganisms 13(9):2050 | 2025 | Prospective in vitro | 75 CRS patients; 54 Staphylococcal isolates from sinonasal tissue | Sub-inhibitory (1/8–1/2 MIC = 0.78–3.1 mg/mL) and supra-inhibitory (2×–8× MIC = 12.4–49.6 mg/mL) concentrations | 3.1 mg/mL prevented biofilm formation in 77.8% of isolates; 49.6 mg/mL eradicated formed biofilm in 81.5% of isolates; effects dose- and strain-dependent; comparable efficacy in CRSwNP and CRSsNP |
| Wee JH, Park JH, Park MW, et al. Diagnostics 14(15):1678 | 2024 | Single-blind RCT | 49 CRSsNP patients post-ESS (NAC n=24, saline n=25) | 1,600 mg NAC in 250 mL saline; 125 mL/nostril 3×/day for 30 days | Significant improvement at 2 weeks in postnasal drip (VAS 1.0 vs 2.6, p=0.041), olfaction (0.8 vs 4.7, p=0.003), and crust (1.5 vs 3.6, p=0.034) vs saline; well tolerated; no adverse events; differences not significant at 1 and 3 months |
| Blasi F, Page C, Rossolini GM, et al. Respir Med 117:190–197 | 2016 | Systematic review | In vitro + clinical evidence for respiratory tract biofilms | Multiple concentrations and routes reviewed | NAC effective at inhibiting biofilm formation, disrupting preformed biofilms (initial and mature), and reducing bacterial viability; recommended as candidate for biofilm prevention/treatment |
| Dinicola S, De Grazia S, Carlomagno G, Pintucci JP. Eur Rev Med Pharmacol Sci 18:2942–2948 | 2014 | Systematic review | In vitro studies across multiple bacterial species | Variable concentrations | NAC confirmed as “powerful molecule to destroy bacterial biofilms”; promotes antibiotic permeability to deeper biofilm layers |
| Zhao T, Liu Y. BMC Microbiol 10:140 | 2010 | In vitro | P. aeruginosa clinical isolates | 0.5–40 mg/mL | MIC range 10–40 mg/mL; biofilm detachment at 0.5 mg/mL; complete disruption at 10 mg/mL; synergy with ciprofloxacin; EPS reduction 27.6% at 0.5 mg/mL, 44.6% at 1 mg/mL |
| Olofsson AC, Hermansson M, Elwing H. Appl Environ Microbiol 69:4814–4822 | 2003 | In vitro | S. epidermidis, E. coli, S. aureus | 0.5–4 mg/mL | NAC reduced extracellular polysaccharide production and biofilm formation on solid surfaces in dose-dependent manner |
| Pérez-Giraldo C, Rodríguez-Benito A, Morán FJ, et al. J Antimicrob Chemother 39:643–646 | 1997 | In vitro | S. epidermidis clinical isolates | 0.5–4 mg/mL | NAC at sub-MIC concentrations significantly reduced biofilm formation by S. epidermidis |
6. Patent Landscape
A search of Google Patents, USPTO, and Justia Patents databases (conducted April 2026) for patents and patent applications related to N-acetylcysteine + biofilm and/or N-acetylcysteine + sinusitis identified the following relevant filings:
| Patent / Application | Title | Assignee | Filed | Status | Relevance |
|---|---|---|---|---|---|
| US 2021/0315849 A1 | Compositions and Methods for Treating One or More Ailments with a Nasal Rinse Comprising N-Acetylcysteine | Individual inventor | 2021 | Published application | Claims a nasal rinse composition containing NAC + salt + alkaline buffering agent for inflammatory nasal/sinus diseases; does not specifically claim biofilm disruption as adjunct to antibiotics in CRS |
| US 9,797,898 B2 | Methods and Devices for Using Mucolytic Agents Including N-Acetyl Cysteine (NAC) | — | 2017 | Granted | Claims devices and methods for delivering mucolytic agents including NAC; focused on device/delivery mechanism rather than the biofilm-disruption therapeutic method |
| US 2017/0100348 A1 | Treatment Regime for Chronic Sinusitis | Microbiome Solutions LLC | 2016 | Abandoned | Claims a treatment regime for chronic sinusitis involving phenol-based biofilm disruption agents; does not claim NAC specifically but addresses the biofilm disruption space in CRS |
Key Observations:
- No granted US patent was identified that specifically claims the method of administering NAC as a biofilm disruption adjunct to antibiotic therapy for chronic rhinosinusitis.
- US 2021/0315849 A1 is the most proximate filing: it claims a NAC-containing nasal rinse composition, but its claims are directed at the formulation (NAC + salt + alkaline buffer) rather than the therapeutic method of biofilm disruption as an adjunct to antibiotics.
- US 9,797,898 B2 covers device/delivery mechanisms for mucolytic agents including NAC, not the specific therapeutic use as a biofilm disruptor in CRS.
- US 2017/0100348 A1 addresses biofilm disruption in chronic sinusitis but claims phenol-based agents, not NAC. This application was abandoned.
- The therapeutic use of NAC for biofilm disruption in CRS has been described in peer-reviewed literature since at least 1997 (Pérez-Giraldo et al.) with CRS-specific clinical evidence published by 2024 (Wee et al.) and 2025 (Jotic et al.).
This disclosure is intended to supplement the existing body of public-domain evidence with a consolidated, enabling description that satisfies the requirements for anticipatory prior art under 35 U.S.C. § 102(a)(1).
7. Public-Domain Dedication
This defensive disclosure is dedicated to the public domain under the Creative Commons CC0 1.0 Universal Public Domain Dedication.
To the extent possible under law, the author has waived all copyright and related or neighboring rights to this work. This work is published from the United States of America.
Legal text: https://creativecommons.org/publicdomain/zero/1.0/legalcode
Purpose of this dedication: To establish a dated, publicly accessible, enabling disclosure that constitutes prior art under 35 U.S.C. § 102(a)(1) and equivalent international patent law provisions. Any person may use, reproduce, modify, distribute, or build upon this disclosure for any purpose, including commercial purposes, without permission or attribution.
Publication platform: Pubroot (https://pubroot.com), a peer-reviewed open-access publication platform with verifiable publication timestamps.
8. Limitations and Disclaimer
This document is not medical advice. The protocols described herein are compiled from published clinical and in vitro studies for the purpose of establishing prior art. They do not constitute a recommendation for clinical use, and they have not been independently validated by the author.
This document is not legal advice. While this disclosure is designed to function as anticipatory prior art under US patent law (35 U.S.C. § 102), its effectiveness in any specific patent proceeding depends on the claims at issue, the filing dates involved, and the interpretation of enablement by the relevant patent office or court. Readers seeking to challenge or defend against specific patent claims should consult a registered patent attorney.
Clinical evidence limitations:
- The only published RCT (Wee et al., 2024) used a small sample (n=49) with short follow-up (3 months) and did not demonstrate statistically significant long-term improvements over saline irrigation alone.
- Most evidence for NAC’s antibiofilm efficacy derives from in vitro studies, which do not always translate to clinical benefit due to differences in biofilm architecture, drug concentration at the site, and host immune factors.
- Optimal NAC concentration, delivery route, frequency, and duration for biofilm disruption in CRS have not been established by adequately powered clinical trials.
- NAC may cause bronchospasm in asthmatic patients when nebulized; gastrointestinal side effects (nausea, vomiting) may occur with oral administration at higher doses.
Conflict of interest: The author has no financial relationship with any NAC manufacturer, patent holder, or pharmaceutical company.
References
Jotic A, Cirkovic I, Bozic D, Savic Vujovic K, Milovanovic J, Folic M, Trivic A, Cvorovic L, Radivojevic N. Antibiofilm Effects of N-Acetyl Cysteine on Staphylococcal Biofilm in Patients with Chronic Rhinosinusitis. Microorganisms. 2025;13(9):2050. doi:10.3390/microorganisms13092050. PMID: 41011382.
Wee JH, Park JH, Park MW, Choi YS, Jung HJ. Sinus Irrigation with N-Acetylcysteine after Endoscopic Sinus Surgery for Chronic Rhinosinusitis: A Preliminary Report of a Single-Blind Randomized Controlled Trial. Diagnostics. 2024;14(15):1678. doi:10.3390/diagnostics14151678. PMID: 39125554.
Blasi F, Page C, Rossolini GM, Pallecchi L, Matera MG, Rogliani P, Cazzola M. The effect of N-acetylcysteine on biofilms: Implications for the treatment of respiratory tract infections. Respir Med. 2016;117:190–197. doi:10.1016/j.rmed.2016.06.015. PMID: 27492531.
Dinicola S, De Grazia S, Carlomagno G, Pintucci JP. N-acetylcysteine as powerful molecule to destroy bacterial biofilms. A systematic review. Eur Rev Med Pharmacol Sci. 2014;18(19):2942–2948. PMID: 25339490.
Zhao T, Liu Y. N-acetylcysteine inhibit biofilms produced by Pseudomonas aeruginosa. BMC Microbiol. 2010;10:140. doi:10.1186/1471-2180-10-140. PMID: 20462423.
Olofsson AC, Hermansson M, Elwing H. N-acetyl-L-cysteine affects growth, extracellular polysaccharide production, and bacterial biofilm formation on solid surfaces. Appl Environ Microbiol. 2003;69(8):4814–4822. doi:10.1128/AEM.69.8.4814-4822.2003. PMID: 12902275.
Pérez-Giraldo C, Rodríguez-Benito A, Morán FJ, Hurtado C, Blanco MT, Gómez-García AC. Influence of N-acetylcysteine on the formation of biofilm by Staphylococcus epidermidis. J Antimicrob Chemother. 1997;39(5):643–646. doi:10.1093/jac/39.5.643. PMID: 9184365.
Stewart PS, Costerton JW. Antibiotic resistance of bacteria in biofilms. Lancet. 2001;358(9276):135–138. doi:10.1016/S0140-6736(01)05321-1. PMID: 11463434.
Psaltis AJ, Weitzel EK, Ha KR, Wormald PJ. The effect of bacterial biofilms on post-sinus surgical outcomes. Am J Rhinol. 2008;22(1):1–6. doi:10.2500/ajr.2008.22.3119. PMID: 18284851.
Foreman A, Psaltis AJ, Tan LW, Wormald PJ. Characterization of bacterial and fungal biofilms in chronic rhinosinusitis. Am J Rhinol Allergy. 2009;23(6):556–561. doi:10.2500/ajra.2009.23.3413. PMID: 19958600.
Marchese A, Bozzolasco M, Gualco L, Debbia EA, Schito GC, Schito AM. Effect of fosfomycin alone and in combination with N-acetylcysteine on E. coli biofilms. Int J Antimicrob Agents. 2003;22(Suppl 2):95–100. doi:10.1016/S0924-8579(03)00232-2. PMID: 14527779.
Leite B, Gomes F, Teixeira P, Souza C, Pizzolitto E, Oliveira R. Combined effect of linezolid and N-acetylcysteine against Staphylococcus epidermidis biofilms. Enferm Infecc Microbiol Clin. 2013;31(10):655–659. doi:10.1016/j.eimc.2012.11.011. PMID: 23642281.
Rosenfeld RM, Andes D, Bhattacharyya N, et al. Clinical practice guideline: Adult sinusitis. Otolaryngol Head Neck Surg. 2007;137(3 Suppl):S1–S31. doi:10.1016/j.otohns.2006.10.032. PMID: 17761281.
Beule A. Epidemiology of chronic rhinosinusitis, selected risk factors, comorbidities, and economic burden. GMS Curr Top Otorhinolaryngol Head Neck Surg. 2015;14:Doc11. doi:10.3205/cto000126. PMID: 26770285.
Millea PJ. N-acetylcysteine: Multiple clinical applications. Am Fam Physician. 2009;80(3):265–269. PMID: 19621836.